Report Detail
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth (Status and Outlook) 2019-2024
- RnM3290110 |
- 09 April, 2019 |
- Global |
- 116 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.
The classification of Amyotrophic Lateral Sclerosis (ALS) Treatment includes Riluzole, Edaravone (Radicava) and Other and the proportion of Edaravone (Radicava) in 2017 is about 67.7%, Radicava is approved in Japan and Korea in 2015, and through the FDA in 2017.
According to this study, over the next five years the Amyotrophic Lateral Sclerosis (ALS) Treatment market will register a 6.7% CAGR in terms of revenue, the global market size will reach US$ 330 million by 2024, from US$ 240 million in 2019. In particular, this report presents the global revenue market share of key companies in Amyotrophic Lateral Sclerosis (ALS) Treatment business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) Treatment market by product type, application, key companies and key regions.
This study considers the Amyotrophic Lateral Sclerosis (ALS) Treatment value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Riluzole
Edaravone (Radicava)
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospital
Drugs Store
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Amyotrophic Lateral Sclerosis (ALS) Treatment market by identifying its various subsegments.
Focuses on the key global Amyotrophic Lateral Sclerosis (ALS) Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyotrophic Lateral Sclerosis (ALS) Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Amyotrophic Lateral Sclerosis (ALS) Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size 2014-2024
- 2.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size CAGR by Region
- 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type
- 2.2.1 Riluzole
- 2.2.2 Edaravone (Radicava)
- 2.2.3 Other
- 2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
- 2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (2014-2019)
- 2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
- 2.4.1 Hospital
- 2.4.2 Drugs Store
- 2.4.3 Other
- 2.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
- 2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application (2014-2019)
3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Players
- 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Players
- 3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Players (2017-2019)
- 3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Players (2017-2019)
- 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Amyotrophic Lateral Sclerosis (ALS) Treatment by Regions
- 4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions
- 4.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
- 4.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
- 4.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
- 4.5 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
5 Americas
- 5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Countries
- 5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
- 5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Countries
- 6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
- 6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment by Countries
- 7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
- 7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment by Countries
- 8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
- 8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast
- 10.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast (2019-2024)
- 10.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Regions
- 10.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Type
- 10.8 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Application
11 Key Players Analysis
- 11.1 Mitsubishi Tanabe Pharma
- 11.1.1 Company Details
- 11.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Mitsubishi Tanabe Pharma News
- 11.2 Sanofi
- 11.2.1 Company Details
- 11.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Sanofi News
- 11.3 Mylan Pharma
- 11.3.1 Company Details
- 11.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Mylan Pharma News
- 11.4 Apotex
- 11.4.1 Company Details
- 11.4.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Apotex News
- 11.5 Glemark Generics
- 11.5.1 Company Details
- 11.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Glemark Generics News
- 11.6 Covis Pharma
- 11.6.1 Company Details
- 11.6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Covis Pharma News
- 11.7 Sun Pharma
- 11.7.1 Company Details
- 11.7.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Sun Pharma News
- 11.8 Lunan Pharma
- 11.8.1 Company Details
- 11.8.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
- 11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Lunan Pharma News
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Amyotrophic Lateral Sclerosis (ALS) Treatment . Industry analysis & Market Report on Amyotrophic Lateral Sclerosis (ALS) Treatment is a syndicated market report, published as Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth (Status and Outlook) 2019-2024. It is complete Research Study and Industry Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
